Ratings for Amgen (NASDAQ:AMGN) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	3	4	11	0	0
Last 30D	0	0	1	0	0
1M Ago	2	2	5	0	0
2M Ago	1	0	2	0	0
3M Ago	0	2	3	0	0

Analysts have set 12-month price targets for Amgen, revealing an average target of $350.61, a high estimate of $432.00, and a low estimate of $304.00. Witnessing a positive shift, the current average has risen by 6.93% from the previous average price target of $327.88.

Deciphering Analyst Ratings: An In-Depth Analysis

The standing of Amgen among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Emily Field	Barclays	Announces	Equal-Weight	$350.00	-
Mohit Bansal	Wells Fargo	Raises	Equal-Weight	$375.00	$325.00
David Amsellem	Piper Sandler	Raises	Overweight	$432.00	$381.00
Jasper Hellweg	Argus Research	Raises	Buy	$400.00	$360.00
Vamil Divan	Guggenheim	Raises	Neutral	$347.00	$305.00
Geoff Meacham	Citigroup	Raises	Neutral	$345.00	$315.00
Terence Flynn	Morgan Stanley	Raises	Equal-Weight	$309.00	$304.00
Carter Gould	Cantor Fitzgerald	Raises	Neutral	$350.00	$315.00
David Risinger	Leerink Partners	Raises	Outperform	$355.00	$305.00
Michael Yee	UBS	Raises	Buy	$390.00	$380.00
Courtney Breen	Bernstein	Maintains	Market Perform	$335.00	$335.00
Gregory Renza	Truist Securities	Raises	Hold	$319.00	$318.00
Michael Yee	UBS	Raises	Buy	$380.00	$317.00
Terence Flynn	Morgan Stanley	Lowers	Equal-Weight	$304.00	$329.00
Mohit Bansal	Wells Fargo	Raises	Equal-Weight	$325.00	$300.00
Evan David Seigerman	BMO Capital	Raises	Outperform	$372.00	$335.00
David Risinger	Leerink Partners	Lowers	Outperform	$305.00	$352.00
Gregory Renza	Truist Securities	Raises	Hold	$318.00	$298.00

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Amgen. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Amgen compared to the broader market.
• Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Amgen's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Amgen's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Amgen analyst ratings.

About Amgen

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Unraveling the Financial Story of Amgen

Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.

Revenue Growth: Amgen's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2025, the company achieved a revenue growth rate of approximately 8.58%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Amgen's net margin excels beyond industry benchmarks, reaching 13.51%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 14.59%, the company showcases effective utilization of equity capital.

Return on Assets (ROA): Amgen's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.48%, the company showcases efficient use of assets and strong financial health.

Debt Management: With a high debt-to-equity ratio of 6.31, Amgen faces challenges in effectively managing its debt levels, indicating potential financial strain.

Analyst Ratings: What Are They?

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

This article was generated by Benzinga's automated content engine and reviewed by an editor.